Aplindore
Top View
- WHO Drug Information Vol. 18, No. 4, 2004
- Revs Le Current-Diseases-MS CN
- 2U11/148243 Al
- Customs Tariff - Schedule Xxi - 1
- PD Medications: Managing Side Effects Led By
- The Involvement of Microglial Activation in Schizophrenia
- Wo 2009/078034 A2
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Predictive Value of Parkinsonian Primates in Pharmacologic Studies: a Comparison Between the Macaque, Marmoset, and Squirrel Monkey S
- Review of the Available Evidence on Oral Dopamine Agonists for Parkinson’S Disease
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- WO 2018/206820 Al 15 November 2018 (15.11.2018) W ! P O P C T
- PSG Newsletter
- Neurogen Hoping Aplindore Data Kick Starts a Rebound
- Ligand Licenses Four Programs to Seelos Therapeutics
- Veyres N, Hamadjida A, Huot P. Predictive Value of Parkinsonian Primates in Pharmacological Studies, a Comparison Between the Macaque, Marmoset and Squirrel Monkey
- WO 2016/100940 Al ©O